4FCD

Potent and Selective Phosphodiesterase 10A Inhibitors


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.02 Å
  • R-Value Free: 0.300 
  • R-Value Work: 0.257 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history

Literature

Novel triazines as potent and selective phosphodiesterase 10A inhibitors.

Malamas, M.S.Stange, H.Schindler, R.Lankau, H.J.Grunwald, C.Langen, B.Egerland, U.Hage, T.Ni, Y.Erdei, J.Fan, K.Y.Parris, K.Marquis, K.L.Grauer, S.Brennan, J.Navarra, R.Graf, R.Harrison, B.L.Robichaud, A.Kronbach, T.Pangalos, M.N.Brandon, N.J.Hoefgen, N.

(2012) Bioorg.Med.Chem.Lett. 22: 5876-5884

  • DOI: 10.1016/j.bmcl.2012.07.076
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • The identification of highly potent and orally active triazines for the inhibition of PDE10A is reported. The new analogs exhibit low-nanomolar potency for PDE10A, demonstrate high selectivity against all other members of the PDE family, and show des ...

    The identification of highly potent and orally active triazines for the inhibition of PDE10A is reported. The new analogs exhibit low-nanomolar potency for PDE10A, demonstrate high selectivity against all other members of the PDE family, and show desired drug-like properties. Employing structure-based drug design approaches, we investigated the selectivity of PDE10A inhibitors against other known PDE isoforms, by methodically exploring the various sub-regions of the PDE10A ligand binding pocket. A systematic assessment of the ADME and pharmacokinetic properties of the newly synthesized compounds has led to the design of drug-like candidates with good brain permeability and desirable drug kinetics (t(1/2), bioavailability, clearance). Compound 66 was highly potent for PDE10A (IC(50)=1.4 nM), demonstrated high selectivity (>200×) for the other PDEs, and was efficacious in animal models of psychoses; reversal of MK-801 induced hyperactivity (MED=0.1mg/kg) and conditioned avoidance responding (CAR; ID(50)=0.2 mg/kg).


    Organizational Affiliation

    Pfizer Neuroscience Princeton, 865 Ridge Road, Monmouth Junction, NJ 08852, USA. malamas.michael@gmail.com




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A
A, B
345Homo sapiensMutation(s): 0 
Gene Names: PDE10A
EC: 3.1.4.17, 3.1.4.35
Find proteins for Q9Y233 (Homo sapiens)
Go to Gene View: PDE10A
Go to UniProtKB:  Q9Y233
Small Molecules
Ligands 3 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
ZN
Query on ZN

Download SDF File 
Download CCD File 
A, B
ZINC ION
Zn
PTFCDOFLOPIGGS-UHFFFAOYSA-N
 Ligand Interaction
0T6
Query on 0T6

Download SDF File 
Download CCD File 
A, B
1-(2-chlorophenyl)-6,8-dimethoxy-3-methylimidazo[5,1-c][1,2,4]benzotriazine
C18 H15 Cl N4 O2
ZXGQTWGCVTUQHJ-UHFFFAOYSA-N
 Ligand Interaction
MG
Query on MG

Download SDF File 
Download CCD File 
A, B
MAGNESIUM ION
Mg
JLVVSXFLKOJNIY-UHFFFAOYSA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
0T6IC50: 0.3 nM (99) BINDINGDB
0T6IC50: 0.28 nM BINDINGMOAD
0T6IC50: 0.28 nM PDBBIND
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.02 Å
  • R-Value Free: 0.300 
  • R-Value Work: 0.257 
  • Space Group: P 21 21 21
Unit Cell:
Length (Å)Angle (°)
a = 51.453α = 90.00
b = 81.503β = 90.00
c = 157.787γ = 90.00
Software Package:
Software NamePurpose
MAR345data collection
HKL-2000data reduction
REFMACrefinement
HKL-2000data scaling
REFMACphasing

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

  • Deposited Date: 2012-05-24 
  • Released Date: 2012-09-05 
  • Deposition Author(s): Parris, K.D.

Revision History 

  • Version 1.0: 2012-09-05
    Type: Initial release
  • Version 1.1: 2013-01-02
    Type: Database references
  • Version 1.2: 2017-11-15
    Type: Refinement description